258 related articles for article (PubMed ID: 21963846)
1. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.
Cao L; Shao M; Schilder J; Guise T; Mohammad KS; Matei D
Oncogene; 2012 May; 31(20):2521-34. PubMed ID: 21963846
[TBL] [Abstract][Full Text] [Related]
2. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.
Yakubov B; Chelladurai B; Schmitt J; Emerson R; Turchi JJ; Matei D
Neoplasia; 2013 Jun; 15(6):609-19. PubMed ID: 23730209
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.
Shao M; Cao L; Shen C; Satpathy M; Chelladurai B; Bigsby RM; Nakshatri H; Matei D
Cancer Res; 2009 Dec; 69(24):9192-201. PubMed ID: 19951993
[TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
5. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
6. Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism.
Condello S; Cao L; Matei D
FASEB J; 2013 Aug; 27(8):3100-12. PubMed ID: 23640056
[TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Brady S; Gao H; Yu D; Reuben J; Mehta K
PLoS One; 2010 Oct; 5(10):e13390. PubMed ID: 20967228
[TBL] [Abstract][Full Text] [Related]
8. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
[TBL] [Abstract][Full Text] [Related]
10. TGF-β-mediated LEFTY/Akt/GSK-3β/Snail axis modulates epithelial-mesenchymal transition and cancer stem cell properties in ovarian clear cell carcinomas.
Matsumoto T; Yokoi A; Hashimura M; Oguri Y; Akiya M; Saegusa M
Mol Carcinog; 2018 Aug; 57(8):957-967. PubMed ID: 29603383
[TBL] [Abstract][Full Text] [Related]
11. ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549.
Song Q; Sheng W; Zhang X; Jiao S; Li F
Tumour Biol; 2014 Feb; 35(2):1377-82. PubMed ID: 24072492
[TBL] [Abstract][Full Text] [Related]
12. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
Agnihotri N; Kumar S; Mehta K
Breast Cancer Res; 2013 Feb; 15(1):202. PubMed ID: 23673317
[TBL] [Abstract][Full Text] [Related]
13. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.
Malfettone A; Soukupova J; Bertran E; Crosas-Molist E; Lastra R; Fernando J; Koudelkova P; Rani B; Fabra Á; Serrano T; Ramos E; Mikulits W; Giannelli G; Fabregat I
Cancer Lett; 2017 Apr; 392():39-50. PubMed ID: 28161507
[TBL] [Abstract][Full Text] [Related]
15. Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.
Condello S; Sima L; Ivan C; Cardenas H; Schiltz G; Mishra RK; Matei D
Cancer Res; 2018 Jun; 78(11):2990-3001. PubMed ID: 29510995
[TBL] [Abstract][Full Text] [Related]
16. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.
Norita R; Suzuki Y; Furutani Y; Takahashi K; Yoshimatsu Y; Podyma-Inoue KA; Watabe T; Sato Y
Cancer Sci; 2017 Mar; 108(3):419-426. PubMed ID: 28064471
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity.
Satpathy M; Shao M; Emerson R; Donner DB; Matei D
J Biol Chem; 2009 Jun; 284(23):15390-9. PubMed ID: 19324884
[TBL] [Abstract][Full Text] [Related]
18. Loss of Krüppel-like factor 9 facilitates stemness in ovarian cancer ascites-derived multicellular spheroids via Notch1/slug signaling.
Wang K; Liu S; Dou Z; Zhang S; Yang X
Cancer Sci; 2021 Oct; 112(10):4220-4233. PubMed ID: 34363722
[TBL] [Abstract][Full Text] [Related]
19. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
Lin CY; Tsai PH; Kandaswami CC; Chang GD; Cheng CH; Huang CJ; Lee PP; Hwang JJ; Lee MT
Mol Cancer; 2011 Jul; 10():87. PubMed ID: 21777419
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase is a tumor cell and cancer stem cell survival factor.
Eckert RL; Fisher ML; Grun D; Adhikary G; Xu W; Kerr C
Mol Carcinog; 2015 Oct; 54(10):947-58. PubMed ID: 26258961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
